keyword
https://read.qxmd.com/read/37785523/investigating-pet-responses-to-treatment-in-nodular-lymphocyte-predominant-hodgkin-lymphoma
#21
JOURNAL ARTICLE
N J Park, S M Hiniker, H H Guo, R H Advani, R T Hoppe, M S Binkley
PURPOSE/OBJECTIVE(S): There is no standard treatment for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Although response by positron emission tomography (PET) for classic Hodgkin lymphoma (cHL) has allowed for response-adapted treatment, similar approaches for NLPHL have not been developed. This is in part due to the lack of data for PET response to treatment. Therefore, we sought to investigate PET responses to management for NLPHL. MATERIALS/METHODS: We retrospectively identified 47 patients who were diagnosed with or treated for NLPHL between 2001-2018 at a single institution and underwent a staging PET...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37785516/outcomes-of-patients-with-transformed-diffuse-large-b-cell-lymphoma-dlbcl
#22
JOURNAL ARTICLE
J Nakashima, R Cruz-Chamarro, J Laborde, S Kim
PURPOSE/OBJECTIVE(S): There is limited data regarding the results of treating transformed Diffuse Large B-Cell Lymphoma, including the influence of radiation therapy on their overall prognosis. Thus, we aimed to investigate the clinical outcomes of transformed DLBCL patients treated at a single institution. MATERIALS/METHODS: We reviewed clinical features and outcomes of 27 patients with biopsy confirmed transformed Diffuse Large B-cell Lymphoma (DLBCL) treated at a single institution from 2005 and 2014...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37785500/impact-of-salvage-versus-palliative-dose-bridging-radiation-therapy-on-local-control-and-overall-survival-in-patients-with-dlbcl-receiving-cd19-car-t-cell-therapy
#23
JOURNAL ARTICLE
K Kiser, A F Cashen, Z D Crees, A Ghobadi, J C Yang
PURPOSE/OBJECTIVE(S): In patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), radiation therapy (RT) can be used to "bridge" patients during the period of chimeric antigen receptor T cell (CAR T) manufacturing. Although RT has been shown to improve local control (LC) in patients who receive RT versus do not, it is unknown whether there is an optimal dose. MATERIALS/METHODS: This was a retrospective study of patients with DLBCL who received bridging RT and CAR T cell therapy between 8/2021 and 12/2022 at a single institution (IRB #202103122)...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37784518/consolidative-radiotherapy-for-residual-pet-avid-disease-on-day-30-post-car-t-cell-therapy-in-non-hodgkin-lymphoma
#24
JOURNAL ARTICLE
O Saifi, S C Lester, W G Rule, W Breen, B J Stish, A Rosenthal, J Munoz, Y Lin, P Johnston, S M Ansell, J Paludo, A Khurana, J Villasboas Bisneto, Y Wang, M Iqbal, M Alhaj Moustafa, H S Murthy, M Kharfan-Dabaja, J L Peterson, B S Hoppe
PURPOSE/OBJECTIVE(S): Up to30% of non-Hodgkin lymphoma (NHL) patients achieve a partial response (PR) to anti-CD19 Chimeric Antigen Receptor T-cell Therapy (CART) on day +30. Most PR patients relapse and only 30% achieve spontaneous complete response (CR) without additional therapies. This study is the first to report on the role of consolidative radiotherapy (cRT) for PR PET-avid disease on day +30 post-CART in NHL. MATERIALS/METHODS: Aretrospective review across 3 institutions from 2018 to 2022 identified 60 patients with B-cell NHL who received CART and achieved PR (Deauville 4-5) with <5 PET-avid disease sites on day +30...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37735258/patterns-of-pet-positive-residual-tissue-at-interim-restaging-and-risk-of-treatment-failure-in-advanced-stage-hodgkin-s-lymphoma-an-analysis-of-the-randomized-phase-iii-hd18-trial-by-the-german-hodgkin-study-group
#25
JOURNAL ARTICLE
Justin Ferdinandus, Lutz van Heek, Katrin Roth, Markus Dietlein, Hans-Theodor Eich, Christian Baues, Peter Borchmann, Carsten Kobe
PURPOSE: Response-adapted treatment using early interim functional imaging with PET after two cycles of chemotherapy (PET-2) for advanced-stage Hodgkin's lymphoma (AS-HL) is the standard of care in several countries. However, the distribution of residual metabolic disease in PET-2 and the prognostic relevance of multiple involved regions have not been reported to date. METHODS: We retrospectively analyzed data from all PET-2-positive patients included in HD18. Residual tissue was visually compared with reference regions according to the Deauville score (DS)...
September 22, 2023: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/37734837/validation-of-the-%C3%AE-suv-max-for-interim-pet-interpretation-in-diffuse-large-b-cell-lymphoma-on-the-basis-of-the-gained-clinical-trial
#26
JOURNAL ARTICLE
Emmanuel Itti, Paul Blanc-Durand, Alina Berriolo-Riedinger, Salim Kanoun, Françoise Kraeber-Bodéré, Michel Meignan, Elodie Gat, Steven Le Gouill, René-Olivier Casasnovas, Caroline Bodet-Milin
The GAINED phase 3 trial (ClinicalTrials.gov identifier: NCT01659099) evaluated a PET-driven consolidative strategy in patients with diffuse large B-cell lymphoma. In this post hoc analysis, we aimed to compare the prognostic value of the per-protocol PET interpretation criteria (Menton 2011 consensus) with the change in the SUVmax (ΔSUVmax ) alone. Methods: Real-time central review of 18 F-FDG PET/CT was performed in 581 patients after 2 cycles (PET2) and 4 cycles (PET4) of immunochemotherapy using the Menton 2011 criteria, combining the ΔSUVmax (cutoffs of 66% and 70% at PET2 and PET4, respectively) and the Deauville scale...
November 2023: Journal of Nuclear Medicine
https://read.qxmd.com/read/37685372/prognostic-value-of-fdg-pet-ct-in-patients-with-nodal-peripheral-t-cell-lymphoma
#27
JOURNAL ARTICLE
Woo Hee Choi, Eun Ji Han, Joo Hyun O, Eun Kyoung Choi, Joon-Il Choi, Gyeongsin Park, Byung-Ock Choi, Young-Woo Jeon, Gi-June Min, Seok-Goo Cho
This study evaluated the prognostic significance of FDG PET/CT in patients with nodal peripheral T-cell lymphoma (PTCL). We retrospectively reviewed patients with histologically confirmed nodal PTCL who underwent FDG PET/CT at baseline, after three cycles of first-line chemotherapy (interim), and at the end of therapy. Response was assessed visually using the Deauville 5-point scale (D5PS); scores of 1, 2, and 3 were considered PET-negative, and scores of 4 and 5 were considered PET-positive. The associations between FDG PET/CT findings and survival were assessed using Cox regression analysis...
September 1, 2023: Diagnostics
https://read.qxmd.com/read/37658560/pet-ct-clinical-role-in-lymphomas
#28
JOURNAL ARTICLE
Nikolaos Papathanasiou
18 F-FDG PET/CT is the imaging modality of choice for the accurate initial staging of most lymphomas. Hodgkin's, Diffuse Large B-cell and follicular lymphomas show avid FDG uptake, while a minority of Non-Hodgkin lymphoma subtypes namely MALT, marginal and small lymphocytic lymphoma demonstrate low or moderate avidity. As a rule of thumb, indolent lymphomas show lower FDG activity than aggressive ones. PET/CT has increased sensitivity in the detection of nodal involvement even in small or normal-sized nodes...
2023: Hellenic Journal of Nuclear Medicine
https://read.qxmd.com/read/37651672/real-world-use-of-positron-emission-tomography-computed-tomography-and-reported-deauville-scores-in-advanced-stage-classic-hodgkin-lymphoma-a-community-oncology-practice-perspective
#29
JOURNAL ARTICLE
Christopher Yasenchak, Nicholas Liu, April Beeks, Michelle Fanale, Nicholas Robert, Ding He, Kristina S Yu
PURPOSE: To evaluate the use of interim positron emission tomography-computed tomography (PET-CT) scans and Deauville 5-point scale (5PS) score reporting for stage III/IV classic Hodgkin lymphoma (cHL) treated frontline (1L) in community oncology settings. METHODS: This retrospective, observational study included adults with stage III/IV cHL initiating 1L doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine, or an escalated dosing regimen of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone within the US Oncology Network between January 2017 and October 2019...
August 31, 2023: JCO oncology practice
https://read.qxmd.com/read/37646672/diffuse-large-b-cell-lymphoma-involving-osseous-sites-utility-of-response-assessment-by-pet-ct-and-good-long-term-outcomes
#30
JOURNAL ARTICLE
Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, Sabela Bobillo Varela, Reiko Nakajima, Laure Michaud, Kanika Gupta, Anastasia Navitski, David Straus, M Lia Palomba, Alison Moskowitz, Ariela Noy, Paul Hamlin, Matthew Matasar, Anita Kumar, Lorenzo Falchi, Joachim Yahalom, Steven Horwitz, Andrew Zelenetz, Anas Younes, Gilles Salles, Heiko Schöder, Erel Joffe
Osseous involvement by diffuse large B-cell lymphoma (DLBCL-bone) is a heterogeneous disease. There is limited data regarding response assessment by positron emission tomography with FDG, which may demonstrate residual avidity despite a complete response. We analyzed clinical data of patients with newly diagnosed DLBCL and identified all cases with DLBCL-bone. End of treatment scans were reviewed by two independent experts classifying osseous lesions into Deauville ≤3; Deauville ≥ 4, or reactive uptake in the bone marrow (M), site of fracture (F) or surgery (S)...
August 31, 2023: Haematologica
https://read.qxmd.com/read/37578376/investigating-the-influence-of-long-axial-versus-short-axial-field-of-view-pet-ct-on-stage-migration-in-lymphoma-and-non-small-cell-lung-cancer
#31
JOURNAL ARTICLE
Ian Alberts, Sigrid Seibel, Song Xue, Marco Viscione, Clemens Mingels, Hasan Sari, Ali Afshar-Oromieh, Andreas Limacher, Axel Rominger
OBJECTIVES: The objective of this study was to evaluate the influence of a long-axial field-of-view (LAFOV) on stage migration using a large single-centre retrospective cohort in lymphoma and non-small cell lung cancer (NSCLC). METHODS: A retrospective study is performed for patients undergoing PET/computed tomography (CT) on either a short-axial field-of-view (SAFOV) or LAFOV PET/CT system for the staging of known or suspected NSCLC or for therapeutic response in lymphoma...
August 15, 2023: Nuclear Medicine Communications
https://read.qxmd.com/read/37524200/the-variation-of-quantitative-parameters-and-deauville-scores-with-different-reconstruction-algorithms-in-fdg-pet-ct-imaging-of-lymphoma-patients
#32
JOURNAL ARTICLE
Mustafa Genc, Nilufer Yildirim, Nazim Coskun, Elif Ozdemir, Seyda Turkolmez
INTRODUCTION AND OBJECTIVES: 18F-FDG PET with the Deauville score (DS) is a unique semiquantitative method for lymphoma. However, type of standard uptake values (max, mean, and peak) reconstruction algorithms could affect DS. We compared the Bayesian Penalized Likelihood reconstruction algorithm (BPL) with Ordered Subsets Expectation Maximization (OSEM) on quantitative parameters and DS in lymphoma. We investigated the effect of the size of the lymph node on quantitative variation. PATIENTS AND METHODS: Raw PET data of 255 lymphoma patients were reconstructed separately with Q...
July 29, 2023: Revista española de medicina nuclear e imagen molecular
https://read.qxmd.com/read/37519806/prognostic-value-of-18f-fdg-pet-ct-in-patients-with-meta-static-breast-cancer-treated-with-cyclin-dependent-inhibitors
#33
JOURNAL ARTICLE
Alessio Annovazzi, Sandra Rea, Daria Maccora, Laura Pizzuti, Gianluigi Ferretti, Patrizia Vici, Federico Cappuzzo, Rosa Sciuto
OBJECTIVE: The addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy impressively improved the outcome of patients with hormone receptor-positive metastatic breast cancer. Despite their great efficacy, not all patients respond to treatment and many of them develop acquired resistance. The aim of this retrospective study was to assess the role of [18F]-FDG PET/CT in predicting PFS and OS in breast cancer patients treated with CDK4/6i. METHODS: 114 patients who performed an [18F]-FDG PET/CT scan before (PET1) and 2-6 months (PET2) after starting treatment were retrospectively enrolled...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37501554/a-retrospective-head-to-head-comparison-of-the-lugano-classification-and-percist-for-fdg-pet-ct-response-assessment-in-diffuse-large-b-cell-lymphoma
#34
JOURNAL ARTICLE
Nicklas B Nielsen, Oke Gerke, Anne L Nielsen, Karen Juul-Jensen, Thomas S Larsen, Michael B Møller, Malene G Hildebrandt
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma. European guidelines recommend FDG-PET/CT for staging and end of treatment (EOT) response assessment, mid-treatment response assessment is optional. We compared the Lugano Classification and PET Response Criteria In Solid Tumors (PERCIST) for FDG-PET/CT response assessment in DLBCL head-to-head. METHODS: We retrospectively included patients with DLBCL who underwent first-line R-CHOP(-like) therapy (2013-2020)...
July 27, 2023: Clinical Physiology and Functional Imaging
https://read.qxmd.com/read/37403255/positron-emission-tomography-adapted-therapy-in-low-risk-diffuse-large-b-cell-lymphoma-results-of-a-randomized-phase-iii-non-inferiority-trial
#35
JOURNAL ARTICLE
Qing Shi, Yang He, Hong-Mei Yi, Rong-Ji Mu, Xu-Feng Jiang, Di Fu, Lei Dong, Wei Qin, Peng-Peng Xu, Shu Cheng, Qi Song, Sai-Juan Chen, Li Wang, Wei-Li Zhao
BACKGROUND: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) but whether the same efficacy can be achieved with reduced chemotherapy regimen of four cycles for non-bulky DLBCL patients with an IPI of 1 remains unclear. This study compared four cycles versus six cycles of chemotherapy in non-bulky low-risk DLBCL patients with negative interim positron emission tomography with computed tomography (PET-CT, Deauville 1-3), irrespective of age and other IPI risk factors (IPI 0-1)...
July 4, 2023: Cancer Communications
https://read.qxmd.com/read/37396807/impact-of-minimal-residual-disease-standardised-assessment-by-fdg-pet-ct-in-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-enrolled-in-the-imaging-sub-study-of-the-forte-trial
#36
JOURNAL ARTICLE
Elena Zamagni, Stefania Oliva, Francesca Gay, Andrea Capra, Delia Rota-Scalabrini, Mattia D'Agostino, Angelo Belotti, Monica Galli, Manuela Racca, Renato Zambello, Barbara Gamberi, Domenico Albano, Luca Bertamini, Annibale Versari, Mariella Grasso, Nicola Sgherza, Claudia Priola, Francesca Fioritoni, Francesca Patriarca, Gabriella De Cicco, Tania Villanova, Anna Pascarella, Pietro Zucchetta, Paola Tacchetti, Stefano Fanti, Katia Mancuso, Simona Barbato, Mario Boccadoro, Pellegrino Musto, Michele Cavo, Cristina Nanni
BACKGROUND: 18F-FDG-PET/CT is the current standard technique to define minimal residual disease (MRD) outside the bone marrow (BM) in multiple myeloma (MM), recently standardised applying the Deauville scores (DS) to focal lesions (FS) and bone marrow uptake (BMS) and defining the complete metabolic response (CMR) as uptake below the liver background (DS <4). METHODS: In this analysis, we aimed at confirming the role of CMR, and complementarity with BM multiparameter flow cytometry (MFC) at 10-5 , in an independent cohort of newly diagnosed transplant-eligible MM patients previously enrolled in the phase II randomised FORTE trial...
June 2023: EClinicalMedicine
https://read.qxmd.com/read/37385118/schrodinger-s-cat-and-deauville-5-point-scoring
#37
JOURNAL ARTICLE
Yingbing Wang, David Chow, Shalini Santoshi Indrakanti, Edwin Lincoln Palmer, James Arthur Scott
No abstract text is available yet for this article.
June 24, 2023: Clinical Imaging
https://read.qxmd.com/read/37370922/analysis-of-positive-results-of-18-f-fdg-pet-ct-imaging-after-hematopoietic-stem-cell-transplantation-in-lymphoma
#38
JOURNAL ARTICLE
Na Dai, Rongcui Cai, Shengming Deng, Shibiao Sang
PURPOSE: The purpose of this study was to differentiate between false-positive and true-positive positron emission tomography (PET) results after hematopoietic stem cell transplantation (SCT) for lymphoma involvement by analyzing several clinical variables and specific imaging features. PATIENTS AND METHODS: Patients with lymphoma who received SCT and underwent post-transplantation 18 F-FDG PET/CT scans between January 2013 and April 2021 at our institution were included...
June 11, 2023: Diagnostics
https://read.qxmd.com/read/37297971/efficacy-of-residual-site-radiation-therapy-isrt-in-patients-with-primary-mediastinal-lymphoma-with-deauville-score-4-following-r-cht-results-of-a-retrospective-mono-institutional-study
#39
JOURNAL ARTICLE
Giuseppe Facondo, Mattia Serio, Gianluca Vullo, Maria Paola Bianchi, Sabrina Pelliccia, Alice Di Rocco, Tiziana Lanzolla, Maurizio Valeriani, Arianna Di Napoli, Agostino Tafuri, Maurizio Martelli, Mattia Falchetto Osti, Vitaliana De Sanctis
BACKGROUND: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT). METHODS: Thirty-one patients with PMBCL were recruited. After completion of R-ICHT, patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and were treated with adjuvant RSRT...
May 31, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37257195/interim-pet-guided-treatment-for-early-stage-nlphl-a-subgroup-analysis-of-the-randomized-ghsg-hd16-and-hd17-studies
#40
JOURNAL ARTICLE
Dennis A Eichenauer, Ina Bühnen, Christian Baues, Carsten Kobe, Helen Kaul, Richard Greil, Alden Moccia, Joseé M Zijlstra, Bernd Hertenstein, Max S Topp, Marianne Just, Bastian von Tresckow, Hans-Theodor Eich, Michael Fuchs, Markus Dietlein, Sylvia Hartmann, Andreas Engert, Peter Borchmann
The optimal first-line treatment for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) diagnosed in early stages is largely undefined. We, therefore, analyzed 100 NLPHL patients treated in the randomized HD16 (early-stage favorable; n = 85) and HD17 (early-stage unfavorable; n = 15) studies. These studies investigated the omission of consolidation radiotherapy (RT) in patients with a negative interim positron emission tomography (iPET) (ie, Deauville score <3) after chemotherapy (HD16: 2× doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]; HD17: 2× escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPP] plus 2× ABVD)...
August 10, 2023: Blood
keyword
keyword
91275
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.